



August 28, 2014

|                   |                                  |
|-------------------|----------------------------------|
| Company Name      | 3 - D M a t r i x , L t d .      |
| A d d r e s s     | 3-2-4, Kojimachi, Chiyoda, Tokyo |
| P r e s i d e n t | Kentaro Takamura                 |
| Code Number       | 7777                             |
| C o n t a c t     | Director Tomoyuki Arai           |
| T E L             | +81 3 (3511)3440                 |

**Absorbable Hemostat “PuraStat®”**  
**Commencement of clinical use in Germany**

The 3-D Matrix group has been working towards starting clinical use of absorbable hemostat “PuraStat®” since obtaining CE marking for the product on January 14, 2014. The company hereby announces that on August 26, 2014, clinical use of the product has commenced at the Heart and Diabetes Center NRW in Germany, one of the major markets for the product in Europe.

Heart and Diabetes Center NRW, Clinic for Thoracic and Cardiovascular Surgery, Michiel Morshuis, M.D. conducted the clinical use to control bleeding during a cardiovascular surgical procedure. Heart and Diabetes Center NRW is a flagship hospital conducting approximately 5,000 cardiovascular surgery cases annually.

With the commencement of clinical use, the company aims to further promote clinical use of PuraStat® in our core European markets, and expand the distribution of the product through an exclusive agreement with a marketing partner.

This announcement does not influence the earning forecast of the company at this moment.